Biotechnology
A growing biotech needs inspection-ready validation and clinical documentation without building a large validation department first. Cybroscape is designed for that stage: AI-drafted deliverables your people review and approve, priced for mid-sized teams.
Biotech companies face the same Annex 11 and 21 CFR Part 11 obligations as a large manufacturer, usually without a dedicated validation function. The practical answer is correct GAMP categorisation, leveraged supplier evidence and a lean but complete lifecycle — not a scaled-down copy of a large pharma template, which is where most of the avoidable cost comes from.
Identify The Roadblocks Slowing Your Growth
These challenges compound: cycles slow, scaling gets harder, and inspection posture drifts.
Regulations We Cover
Every biotech engagement is mapped to the regulations your inspectors will use.
GxP
- FDA 21 CFR Part 11
- EU Annex 11 / Annex 22
- ICH E3
- GAMP 5 Second Edition
- 01ResearchELNLIMSResearch data that can support a filing
- 02Process developmentELNData historianA tech-transfer package that holds up
- 03Clinical trialsEDCeTMFCTMSTrial records kept to ICH E6
- 04Clinical manufacturingMES or paper batch recordsLIMSGMP from the first clinical batch
- 05SubmissionRIMDocument managementSubmission content traceable to source
Services & Products For Biotechnology
- CSV
- CSA
- AI Validation
- CSR Authoring
- Safety Narratives
- AI Governance
- GxP CopilotAI-native, CSA-first computer system validation for Life Sciences.
- TraceDraftValidated, source-traceable document generation for clinical and regulatory submissions.
- Cybroscape eQMSAn agentic quality management system for pharma, biotech and medical devices.
- Study IntelligenceAgentic intelligence across your studies — samples, biomarker data, operations and vendors in one place.
GxP Copilot at a Series-B biotech
A Series-B biotech deploying its first regulated LIMS had eight weeks before go-live and no QA function.
Read the case studyIND Preparation Without a Dedicated Validation Team
Series A and B biotech companies face a paradox: the regulatory obligations that accompany an IND submission are identical whether you have 20 people or 200, but the resource to meet them is a fraction of what large pharma carries. 21 CFR Part 11 compliance for electronic records, GAMP 5-aligned qualification of your Benchling or LabWare LIMS, and a defensible audit trail strategy are not optional — they are what allows your clinical data to stand up in a regulatory submission.
Cybroscape's embedded validation practice for growth-stage biotech functions as an on-demand qualification team. We scope and execute LIMS qualification, Part 11 gap assessments, and VMP development within the sprint cadence of a biotech team — not the waterfall timelines of a large-pharma engagement. Our approach is built to get IND-ready system validation done quickly, with documentation that anticipates FDA inspection rather than just satisfying an internal checklist.
GAMP 5 and CSA: Getting the Depth Right for Lean Organisations
GAMP 5's software categorisation model — from Category 1 infrastructure to Category 5 custom applications — is widely misapplied in biotech. Teams either over-qualify SaaS platforms with full IQ/OQ/PQ protocols written as if they were custom SCADA systems, or under-qualify bespoke R&D tools that directly generate submission data. Either error wastes resources or creates regulatory exposure that surfaces during a pre-IND or Phase 2 manufacturing inspection.
FDA's 2022 Computer Software Assurance guidance offers biotech companies a better framework: critical thinking over documentation volume. We apply CSA principles to right-size validation effort — heavier testing documentation for high-risk, direct-impact systems; lighter, risk-justified rationale for low-risk commercial platforms. GxP Copilot supports this directly, generating CSA-aligned validation packages that are proportionate, defensible, and fast enough to keep pace with development timelines.
Benchling and LabWare LIMS Qualification for Research-Stage Data
Benchling has become the de facto ELN and LIMS platform for modern biotech, and LabWare remains dominant in analytical QC laboratories. Both present the same challenge: they are highly configurable platforms, and configuration equals customisation under GAMP 5 logic — which means each implementation carries a unique validation obligation that the vendor's standard package does not fully cover.
Our LIMS qualification practice has executed validation programmes across Benchling, LabWare, and LabVantage, with particular depth in assay data capture, chain-of-custody, and 21 CFR Part 11 e-signature implementation. We understand where these platforms generate audit trail gaps in practice — not just in theory — and our test scripts target the failure modes that FDA investigators actually look for during systems-focused inspections.
EU Annex 11 for Biotech Entering European Clinical Development
Biotech companies planning EU clinical trials or pursuing an EMA MAA face EU GMP Annex 11 obligations that are subtly but meaningfully different from 21 CFR Part 11. Annex 11 places greater emphasis on supplier assessment, business continuity, and validation of the entire computerised system life cycle. For a biotech whose systems were originally qualified solely for FDA purposes, this gap can delay EMA scientific advice interactions and CTA approvals.
Cybroscape's regulatory strategy team maps existing Part 11 documentation against Annex 11 requirements, identifying genuine compliance gaps versus superficial structural differences, and producing bridged validation documentation that satisfies both regulatory regimes. This avoids the expensive mistake of running parallel validation programmes when a single integrated approach would serve both the FDA and EMA inspection tracks.
Clinical Writing Bottleneck at IND and CSR Stage
The moment a biotech company's Phase 1 trial completes, the clinical writing workload arrives in a single wave: CSR, investigator brochure update, safety narratives, and the first IND annual report. For organisations without an in-house medical writing function, this creates a capacity crisis that delays subsequent regulatory submissions and strains the CRO relationship at exactly the point where scientific momentum should be building.
TraceDraft was designed for exactly this bottleneck. It ingests your protocol, SAP, and TLG outputs to generate a structured CSR first draft aligned to ICH E3 — with source traceability back to the underlying study data built in. Your clinical operations lead reviews a near-complete document rather than a blank template. At Series A–C scale, this is the difference between hitting your next regulatory milestone on time and slipping by a quarter.
AI Governance for Biotech Without a Full GRC Team
AI tools are entering biotech workflows faster than governance frameworks are being built. AI-assisted protein structure prediction, ML-driven biomarker identification, and automated literature review are already influencing regulated R&D decisions — but the validation and governance frameworks to audit these tools for regulatory submissions are absent in most growth-stage organisations.
GxP Copilot provides the AI governance infrastructure that a lean biotech team can actually operate. It tracks model versions, training data provenance, validation testing, and change history for AI tools used in regulated contexts — generating the evidence documentation that will increasingly be required as AI use in IND and BLA submissions comes under agency scrutiny.
Explore More For Regulated Life Sciences
Biotechnology validation without the backlog.
Bring one system. A biotech validation lead shows you the package it produces.
- We reply within one business day
- We run your URS live on the call
- You get a clear plan for your system